ODTX (Odyssey Therapeutics) Total Operating Expense: $39.67 Mil (TTM As of Mar. 2026)


ODTX Odyssey Therapeutics Inc ODTX
9 GF Score
Price $19.23
! 2 Warning Signs
View Full Analysis

What is Odyssey Therapeutics Total Operating Expense?

Odyssey Therapeutics ODTX +1.91% 9 Total Operating Expense is $39.67 Mil as of Mar. 2026. GuruFocus rates ODTX with a GF Score™ of 9/100. The stock has 2 warning signs investors should review.

Odyssey Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was $39.67 Mil. Odyssey Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $39.67 Mil.

Odyssey Therapeutics Total Operating Expense Related Terms

Odyssey Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Odyssey Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Odyssey Therapeutics Total Operating Expense Chart

Odyssey Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Operating Expense
122.78 134.48 139.70 164.13

Odyssey Therapeutics Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial 0.00 38.88 46.73 0.00 39.67
ODTX
9GF Score
Odyssey Therapeutics Inc ODTX
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Odyssey Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $39.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $39.67 Mil mean?
Odyssey Therapeutics (ODTX) has a Total Operating Expense of $39.67 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Odyssey Therapeutics and its competitors.
Is Odyssey Therapeutics' Total Operating Expense too high?
Odyssey Therapeutics' current Total Operating Expense is $39.67 Mil. Overall, Odyssey Therapeutics has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Odyssey Therapeutics' Total Operating Expense compare to VOR and PHAT?
Odyssey Therapeutics' Total Operating Expense of $39.67 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Odyssey Therapeutics and its competitors. Odyssey Therapeutics's current Total Operating Expense is $39.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Odyssey Therapeutics stock overvalued right now?
Odyssey Therapeutics (ODTX) has a current Total Operating Expense of $39.67 Mil. The current Total Operating Expense is $39.67 Mil. Odyssey Therapeutics' overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Odyssey Therapeutics (ODTX), the current Total Operating Expense is $39.67 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Odyssey Therapeutics Business Description

Address 51 Sleeper Street, Boston, MA, USA, 02210
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
9GF Score

Get the complete analysis for ODTX

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.23
Price